OM — Outset Medical, Inc.

Summary of Outset Medical Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $119.5 million, a 5% increase from 2024, aligning with the high end of revised guidance.
• Product Revenue: $84.8 million, a 5% increase year-over-year.
• Service Revenue: $34.7 million, up 6% from the previous year.
• Non-GAAP Gross Margin: 39.6% for the year, with Q4 gross margin at 42.9%, reflecting a 500 basis point improvement year-over-year.
• Operating Loss: Non-GAAP operating loss narrowed to $13.3 million, a 14% improvement from Q4 2024.
• Net Loss: Non-GAAP net loss of $15 million, down 22% from the prior year.
• Cash Position: Ended Q4 with $173 million in cash, indicating sufficient funds to reach profitability.

2. Strategic Updates and Business Highlights

• Next-Generation Tablo Platform: Recently received FDA clearance, featuring enhanced cybersecurity and operational improvements, expected to launch in Q2 2026.
• Customer Satisfaction: Maintained a high customer satisfaction score above 95%.
• Market Expansion: Tablo is now utilized in approximately 1,000 acute care sites, with ongoing agreements for in-sourcing dialysis services.
• Cost Structure Improvements: Reduced cash usage by $70 million in 2025 and made significant investments in technology and leadership.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $125 million and $130 million, representing a 5% to 9% growth over 2025.
• Gross Margin Expectations: Anticipated to be in the low to mid-40% range, with improvements expected as manufacturing under-absorption diminishes.
• Operating Expenses: Expected to grow at half the rate of revenue growth, indicating continued operating leverage.
• Cash Usage: Anticipated to be lower than the $46 million used in 2025.

4. Bad News, Challenges, or Points of Concern

• Product Revenue Decline: Q4 product revenue was $19.9 million, down from $21 million in Q4 2024, attributed to order timing.
• Sales Cycle Length: Larger deals have longer sales cycles (9 to 12 months or more), which could impact revenue timing and predictability.
• Market Conditions: No significant changes in hospital capital spending were noted, which could affect future sales.

5. Notable Q&A Insights

• Next-Gen Tablo Impact: The new platform is expected to attract interest across various hospital sizes due to enhanced cybersecurity features, although specific ASP details are pending.
• Sales Force Stability: The sales team remains stable post-leadership changes, with ongoing efforts to find a new leader being conducted carefully.
• Pipeline Diversification: The pipeline has grown consistently, with a healthy mix of new and existing customers, including critical access hospitals.
• Gross Margin Projections: While the new Tablo may initially impact margins due to a manufacturing learning curve, it is expected to be a mild effect overall.

This summary encapsulates the key points from Outset Medical's Q4 2025 earnings call, highlighting both the positive developments and challenges faced by the company.